Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Checkpointinhibition bei Zervix-, Vaginal- und Vulvakarzinom

Immuntherapie rezidivierter/refraktärer virusassoziierter gynäkologischer Tumoren

  • 6 Accesses

This is a preview of subscription content, log in to check access.

1

Literatur

  1. 1.

    Naumann RW et al. J Clin Oncol. 2019;37(31):2825-34

  2. 2.

    Long HJ 3rd et al. J Clin Oncol. 2005;23(21):4626-33

  3. 3.

    Tewari KS et al. Lancet. 2017;390(10103):1654-63

  4. 4.

    Chung HC et al. J Clin Oncol. 2019;37(17):70-1478

  5. 5.

    Frenel JS et al. J Clin Oncol. 2017;35(36):4035-41

Download references

Author information

Correspondence to Michael Eichbaum.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Eichbaum, C., Eichbaum, M. Immuntherapie rezidivierter/refraktärer virusassoziierter gynäkologischer Tumoren. InFo Hämatol Onkol 23, 27–28 (2020). https://doi.org/10.1007/s15004-020-7979-6

Download citation